Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Imidafenacin (KRP-197/ONO-8025, IM), 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide, is a new antimuscarinic agent currently under application for the indication of treatment of overactive bladder in Japan. We developed and validated the sensitive and selective bioanalytical methods for the extremely low levels of IM and its metabolite, M-2 (Method 1), M-4 (Method 2) and M-9 (Method 3) in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In each method, plasma sample was extracted by solid phase extraction, separated on a semi-micro high performance liquid chromatography column and detected by tandem mass spectrometer with an atmospheric pressure chemical ionization or ionspray interface. Selected reaction monitoring mode was used for quantification. Each method was found to have acceptable accuracy, precision, stability, selectivity and linearity over the concentration range of 10-500 pg/mL for IM and M-2, 10-1000 pg/mL for M-4 and 50-5000 pg/mL for M-9. Using these analytical methods, concentration profiles of IM and its metabolites in human plasma were successfully determined even in the low pg/mL levels after oral administration of IM at the therapeutic dosage of 0.1 mg.
Masuda
Yuichi
Y
Research Center, Kyorin Pharmaceutical Co. Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan. yuuchi.masuda@mb.kyorin-pharm.co.jp
Kanayama
Norihiro
N
Manita
Shigeru
S
Ohmori
Satoshi
S
Ooie
Tsuyoshi
T
D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D007093:Imidazoles / Q000097:blood* / Q000737:chemistry / Q000378:metabolism; D015394:Molecular Structure; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*
D007093:Imidazoles; C120953:imidafenacin